MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its first quarter 2024 financial results on May 14, 2024. The company is focused on developing iNKT cell therapies for cancer and immune diseases. An executive conference call and webcast will follow to discuss the results and provide a corporate update.
Positive
Focus on developing innovative iNKT cell therapies for cancer and immune diseases.
Announcement of first quarter 2024 financial results to provide transparency to investors.
Negative
- None.
News Market Reaction
On the day this news was published, INKT gained 4.20%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 14, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
Conference Call
Dial-in numbers: 646-307-1963 (U.S. – NY), (800) 715-9871 (U.S. & Canada)
Conference ID: 7888464
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/vc5onn9q.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Investor Contact
917-362-1370
Media Contact
781-674-4428
communications@minktherapeutics.com
FAQ
When will MiNK Therapeutics release its first quarter 2024 financial results?
What is the focus of MiNK Therapeutics, Inc.?
How can investors access the conference call and webcast for the corporate update?
